When Your Sponsor Restructures Mid-Trial, Sites Pay the Operational Price
Coherus cut 30% of staff; Gyre laid off post-acquisition. Sites lose study contacts, amendments stall, and monitoring gaps widen....
Coherus cut 30% of staff; Gyre laid off post-acquisition. Sites lose study contacts, amendments stall, and monitoring gaps widen....
Tufts CSDD puts 82x ROI on AI monitoring agents in Phase 3 oncology. Before sponsors restructure monitoring teams, sites...
Scholar Rock's BLA refiling for SMA drug apitegromab after Catalent Indiana's OAI classification shows how CMO inspection failures translate...
Icon's enterprise-wide Microsoft Copilot deployment and $300M AI investment will reshape how CRAs monitor, query, and escalate — here's...
Phesi finds fewer than 1 in 3 trial protocols connect to real patient data — meaning flawed assumptions reach...
EMA's first 2026 quarterly report shows only 40.5% of EU trials recruiting within 200 days — far below the...